Evaluation of Amantadine as Part of a Multimodal Analgesic Regimen for the Alleviation of Refractory Canine Osteoarthritis Pain
World Small Animal Veterinary Association World Congress Proceedings, 2007
B.D.X. Lascelles1; J. Gaynor2; E.S. Smith1; S. Roe1; D.J. Marcellin-Little1; G. Davidson1; J. Carr1
1Comparative Pain and Orthopedic Research Laboratories, North Carolina State University College of Veterinary Medicine, Raleigh, NC, USA; 2Animal Anesthesia and Pain Management Center, Colorado Springs, CO, USA

This study assessed the analgesic effects of amantadine, in combination with meloxicam, in dogs with osteoarthritis.

Thirty-one client-owned dogs with clinical hind limb lameness despite the use of a non-steroidal anti-inflammatory drug (NSAID) were included. The study was randomized, blinded and placebo controlled with parallel groups. On day 0, dogs were taken off all medications. On day 7, all dogs received meloxicam (approved dosing regimen) for 5 weeks. On day 21, dogs received amantadine (A) (3-5mg/kg once daily per os) or placebo (P) for 21 days, in addition to receiving meloxicam. Assessments were performed on days 0 (prior to study), 7, 21, and 42. Primary outcome measures were blinded owner assessments of activity using client specific outcome measures (CSOM) (days 0, 7, 21 and 42). Data was analyzed using Wilcoxon Signed Rank test.

Both groups improved significantly from day 7 to 21 in CSOM scores for activity. From day 21 to 42, the amantadine group improved further (p=0.0002), but the placebo group did not (p=0.87). In dogs with osteoarthritis pain partly refractory to a NSAID, the ability to perform everyday activities is improved by the addition of amantadine.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Simon C. Roe, BVSc, PhD, DACVS
North Carolina State University
North Carolina, USA

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.


777 W. Covell Blvd., Davis, CA 95616



  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357